Business
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major und
About this update from Scisparc Ltd.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LYbHRS3_v8ob5T6A1Lc.4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030","length":184,"tagName":"p"},{"type":"text","content":"Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).","length":560,"tagName":"p"},{"type":"text","content":"This innovative treatment blends Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced via its partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC).","length":235,"tagName":"p"},{"type":"text","content":"The patent filing underscores the potential promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally. Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options.","length":409,"tagName":"p"},{"type":"text","content":"About Clearmind Medicine Inc.","length":39,"tagName":"p"},{"type":"text","content":"Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel p...